TNNT2 and atrial fibrillation: In addition, patients with sarcomeric gene (e.g., MYH7, TNNT2) variants in hot spot sites that are more frequently associated with HCM development may have higher AF vulnerability in the future than those with gene variants in non-hot spot sites (13, 15).